Freedom

$IBRX Release the Kraken.

Not my words. The man who runs American healthcare said them on Monday night, under a MAHA banner, at a Washington reception most investors have never heard of.

Ever since ImmunityBio's earnings landed, the boards have been three straight days of doom and gloom. Perfect conditions for missing the thing that actually matters.

Because while the panic was soaking up all the attention, something happened behind the scenes that could reshape American healthcare. And at the end of that chain, quietly, sits ImmunityBio. Promised nothing, as you will see. Positioned close.

It did not start Monday. In late January, the founder of ImmunityBio went on this movement's own show and asked it for help. On Monday night, nine months later, the movement declared the road clear.

Each event was easy to miss on its own. Put them side by side and they tell a story.

Every quote below is word for word. At the end, you decide.

THE NIGHT THE FOUNDER WENT ON THEIR SHOW

MAHA, Make America Healthy Again, is the movement Robert F. Kennedy Jr. runs from the top of HHS. Its organizing arm outside government, MAHA Action, is run by Tony Lyons (@tonylyonspub), Kennedy's own book publisher. Weekly livestream. Monthly Washington parties. A tracker they say covers every health bill in the country.

In late January, that livestream had a first-time guest.

Patrick Soon-Shiong (@DrPatrick).

LISTEN TO HOW THEY INTRODUCED HIM

Before Soon-Shiong said a single word, the movement set the stage for him. First, the host named the enemy. Word for word:

"We talk a lot about all the things that we do that make us sick. All the terrible foods that we've been persuaded to put into our body, that we've been lied to, we've been propagandized. And those kinds of things have led to the incredible increase in cancer."

Then, in the same breath, he introduced his guest:

"He is a physician, a scientist... pioneering cancer therapies. But he's also just a visionary... a lot of entrenched groups, a lot of powerful people, would prefer that he didn't have these ideas... that he couldn't actually use these ideas to make people so much more healthy and to cure so much cancer in this country."

And then the line that tells you exactly where this movement places this man:

"He's putting everything on the line. He's going on every podcast. He's at this day and night, because he wants to cure cancer. He believes that he can do it. And so many of these forces are conspiring to slow that down, because they have other priorities."

Hold that sequence. Their diagnosis: poisoned food, rising cancer. Their guest: the man who says he can treat it. That pairing was the movement's choice, not mine. The host speaking is Tony Lyons himself, MAHA's chief organizer, Kennedy's own publisher.

WHAT THE FOUNDER ASKED FOR, AND WHAT MAHA PROMISED

The founder looked at the movement's audience and told them that the thing he has pursued for 35 years is, in his words, "truly I believe a core principle of MAHA."

Then the founder introduced them to IL-15, the molecule he says the National Cancer Institute called "the most important molecule that could cure cancer." And to the drug built on it, ANKTIVA, which wakes up the body's natural killer cells and T cells, the immune cells whose job is hunting cancer. FDA approved, "but just for bladder cancer."

And then Soon-Shiong started dropping lines that should have made every holder sit up:

- "The Saudi government came and visited us and said, we have 37 million people... we want this for our nation. And they just approved it now in Saudi Arabia."

- "I have 13,000 requests now sitting. Desperate calls for this treatment."

- "We need to bring this to this country. It's invented here. And this is really what we really mean by America first."

Tony Lyons listened to all of it. And then the host answered his guest.

Word for word:

"These are ideas that can change real people's lives, cure millions of people from the scourge of cancer that has overtaken this country... we need to find a way to cure cancer. And I want you to help us get there."

And then Lyons made him a promise:

"I want to do everything that I can do to make sure that you get the platform and the access that are necessary to make the arguments. And I believe that those arguments will succeed."

The platform and the access. To help cure the scourge the movement exists to fight. Their words.

That alone would be a story. But a week later the founder came back, and the second call made the first one look shy.

THE SECOND CALL, AND WHO WAS WAITING TO SPEAK

February 4. Same movement. Soon-Shiong opened by going further than in January: "the core essence of MAHA, to make America healthy again, is actually your immune system." Their whole name, his life's work.

And then the ImmunityBio founder stopped explaining and started pleading, straight at Washington:

- "During the Biden administration, four years, 700,000 pages of review. And then finally they gave us the approval for a tiny little piece of bladder cancer."

- "In frustration, I moved my attention to Saudi Arabia, and very quickly, literally quickly, they approved this for lung cancer."

- "I just had a call this morning with the United Arab Emirates, who want this as well. This should be something that Americans should be able to have access to. We are now 13,000 requests and growing."

- "It should not be who you know... it should be anybody and everybody."

- "I'm just struggling, I must say, openly, to convince the current FDA..."

And then one sentence that reads differently now than it did in February:

"Please help me help the American public have access to this."

Those are Soon-Shiong's claims, made on a political platform, and I quote them exactly as that. Now the part that made me sit up.

The speaker who came on right after the founder was Dr. Mehmet Oz.

The sitting administrator of Medicare and Medicaid. Who, Soon-Shiong mentioned, had shared with him his own father's book on the lymphatic system.

Read that again. A plea about FDA access, delivered to the movement's base, with the man who runs Medicare waiting for the microphone.

And how did Tony Lyons close that second visit?

Like this:

"We've got this generation where we've destroyed our immune systems, and so we have to rebuild them and use technologies like yours to strengthen them to get that power back."

Technologies like yours.

That was January and February. The movement heard the ImmunityBio founder, twice, and said so in its own words. But a movement that is being throttled cannot act on what it hears.

Then, last week, the throttle came off.

WHAT CHANGED LAST WEEK

Republicans lost Congress in the midterms. The headlines called it a defeat.

Inside this movement, something else happened entirely.

- Friday, November 6: Susie Wiles' last day as White House chief of staff. Kennedy thanked her publicly the same day, and posted: "Next to me, Stephen Miller is the strongest MAHA supporter in the administration. It's time to unleash the Kraken."

- Monday, November 9: Miller took over the White House.

Three days. A changing of the guard.

And on the very evening Miller took over, the movement threw a party.

MONDAY NIGHT, NOVEMBER 9

MAHA Action's monthly Washington reception. Reporters in the room. And mark that date twice. It was the new chief of staff's first day in power. And it was the same Monday ImmunityBio's earnings landed and the boards went dark.

While the boards filled with doom, Kennedy stood up at that party and explained, calmly and in detail, why he believes the next two years will not look like the first two.

He began with grace for the woman who had just left. Wiles, he told the room, had been "vilified this week," but "without Susie, I wouldn't be here."

Then the other half: "There were things that we didn't get done. And that was very frustrating to me. And they were very, very important things."

Then, what those first two years actually felt like. His words:

"You get throttled in this position by a lot of different people. People in the agency... people in the White House and with access to the White House, and people in Congress."

Then the sentence the clips carried and never explained:

"Every time I tried to do something robust, I would get calls saying, if you do that, we're not going to confirm your appointees."

Here is what that means, because it is genuinely strange.

While his own party held the Senate, every senator had a personal veto to trade: give me what I want, or your people never get the job.

After the midterms?

Once the new Senate is seated in January, confirmations are dead either way. The other party will not confirm his people. His own party can no longer deliver the votes. A threat to withhold what nobody can grant is an empty threat.

"The Senate no longer has any leverage over me."

Sit with that.

Losing the election is what freed him. That is the paradox the room was toasting.

THE DINNER THE DAY AFTER HALLOWEEN

Then Kennedy told the room about a dinner at Stephen Miller's house, the day after Halloween. Where the incoming White House chief of staff said to the secretary:

"I'm the only one in the administration who's more radical than you are on MAHA."

And Kennedy, about the road ahead:

"I don't think anything is going to get in our way now."

What exactly are they going to do? Kennedy would not say. "There's a lot of press here, and I don't want to unveil our strategies."

Only this:

"I said, just write: release the kraken. Because that's what we're about to do. And so stand by."

CANCER WAS IN THE ROOM TOO

Tony Lyons had opened that same night by naming the destination:

"We could be the beacon of health in the world, so that people would come here for treatment."

People would come HERE. For treatment. Hold that phrase against everything you read above from January.

And then Kennedy, introducing an Iowa candidate, named the issue that now dominates that state's politics:

"Iowa has the highest cancer rate in the country. Iowa and Kentucky, the fastest growing cancer rate in the entire world. And it's coming from the nitrates and the pesticides and all of these contaminants."

That cause is Kennedy's claim, and I quote it as exactly that. But hear what the room heard: the movement that just declared nothing is in its way treats cancer as its unfinished business.

So run the thread once. In January, this movement said poisoned food is driving cancer up, and put ImmunityBio's founder on its own stage, describing Soon-Shiong as a man fighting "day and night, because he wants to cure cancer."

In February it told him: we have to rebuild our immune systems "and use technologies like yours."

And on Monday night it declared the road clear.

Who stood on their stage talking about that disease in January and February, you already know.

HAVE WE HEARD ALL OF THIS BEFORE?

Yes. We have. And this is the section that keeps your feet on the floor.

The 2024 campaign promised sweeping change. Two years in, the movement's own stage recited what actually landed:

- Dietary guidelines rewritten around one line: eat real food

- A draft FDA policy expanding access to six peptides

- Psychedelic-therapy research advancing, including trials in veterans' hospitals

- Cell phone legislation in schools in half the states, which Kennedy credits to the movement

- By the organizer's own count: 230 state bills backed this year, 31 signed into law across more than a dozen states, under both parties

A real list. And not the 2024 list. No transformation of chronic disease yet. Nothing in those plans that touches cancer care.

Although one cancer move did land this year, from the FDA itself: in October it approved ANKTIVA's expansion to papillary bladder tumors nearly three months ahead of its own deadline. Nobody promised that either. It happened anyway.

They delivered some of it. Not all of it. Both facts are true, and the room knows both.

That is exactly why "I don't think anything is going to get in our way now" was the sentence of the night.

So calibrate: the next two years will probably rhyme.

Some of it. Not all of it.

QUESTION ONE: DO THEY BELIEVE THE SCIENCE?

Does this movement believe in the science ImmunityBio is built on, immune restoration through NK cells and IL-15?

On the record: yes.

- They put its inventor on their own platform twice in two weeks

- Their host introduced him as a man working "day and night, because he wants to cure cancer" while "forces are conspiring to slow that down."

- Their chief organizer promised him "the platform and the access."

- The man who runs Medicare spoke right after him

- And in neither session did anyone push back. The movement embraced the pitch as its own

Tick the first box.

QUESTION TWO: DID ANYONE NAME IMMUNITYBIO ON MONDAY?

On Monday night, with the road supposedly clear, did anyone name ImmunityBio, ANKTIVA, or cancer therapeutics in the plans?

No. Peptides, psychedelics research, vaccine studies, food. Not one word about cancer drugs. Not one company in those plans.

The second box is empty.

That is the whole picture. One tick, one empty box, and anyone who tells you more than that is selling you a feeling.

THE OTHER EMPIRE AT THE TABLE

One more thread, because ImmunityBio is not the only thing Patrick Soon-Shiong brings to Washington.

Around the public company sits his private Nant empire, a decade and a half in the making, built on one idea: American healthcare runs on broken plumbing, and somebody should rebuild it.

- AirStrip, a NantWorks company, puts live hospital monitoring on a doctor's phone, and partnered with GE HealthCare to push that into hospital systems nationwide

- His fiber-optic work is aimed, in the founder's own words, at "moving data at the speed of light.

- His newest tease, alongside one of the world's top photonic scientists: detecting disease with light itself

- And NantIQ, the AI app for giving patients their own records, which Soon-Shiong announced at the White House in July 2025, at the launch of the government's health-data initiative, standing alongside Apple, Google and Amazon, thanking Dr. Oz by name

Now ask the question the loudest voices skip. When one founder keeps handing the government working machinery for its health agenda, does the goodwill stay in one pocket? History says no.

Is any of this a promise to ImmunityBio? No. But every useful thing the Nant side gives this administration makes the founder harder to ignore when his medicine asks for a hearing.

WHAT IS HIS, AND WHAT IS THE COMPANY'S

Now the precision, because precision matters most when people are scared. Look at where that Nant machinery lives:

- NantIQ, the patient-records app: private
- The health-data networks: private
- The laser-based diagnostics: private
- AirStrip: private

Whatever doors this movement opens for those, the value lands with the founder, not inside $IBRX shares. The public company owns the medicine, ANKTIVA. Keep the two separate, because the loudest voices this week will not.

Can they deliver the next two years?

Unknown.

The first two already answered that in advance: partially.

Count on some. Never on all.

TWO ROOMS, NINE MONTHS APART

Nobody in power has promised ImmunityBio anything.

Keep that fact where you can see it.

Now hold the sequence one last time.

In January and February, the movement that runs American health policy heard the founder of ImmunityBio say that restoring the immune system, the exact thing his approved drug ANKTIVA exists to do, is the core of what their own name means.

Their organizer promised him a platform.

The man who runs Medicare took the microphone right after him. And the founder's last words to them were: "please help me help the American public have access to this."

On Monday night, November 9, the very evening ImmunityBio's earnings had the boards in despair, that same movement stood up and declared the road clear.

The Senate has no leverage. The new White House chief of staff calls himself more radical on their mission than Kennedy himself.

And the secretary who oversees the FDA said, with reporters in the room: "I don't think anything is going to get in our way now."

Release the kraken. Stand by.

What swims out, and whether any of it swims toward ImmunityBio, is promised to no one.

I connected the dots as far as the receipts reach.

Not one inch further.

Whether they connect the rest of the way, nobody can guarantee you, and nobody should.

Read it again. Then you decide.

$IBRX On paper, today reads like a catastrophe. A loss of about a billion dollars for the year so far. Revenue that slipped for the first time in two years.

Breathe. Almost none of it means what it looks like. And for the people this disease is actually about, today was not a bad day at all. It was another door opening.

FOR THE PATIENTS, NOTHING GOT WORSE

Start there, because they are the ones for whom nothing today was a setback. A loss on an accounting statement does not change a single thing about their treatment. The drug they rely on is exactly where it was yesterday, still approved, still shipping, still working. Whatever the headlines did today, not one patient is worse off for it.

AND IT ACTUALLY GOT BETTER

If anything, their position improved. Four weeks ago, a person facing high-grade bladder cancer had one approved version of this medicine to reach for. Today they have more. Last month the FDA widened it to a second kind of tumor. This morning a pivotal trial showed it can work even earlier, before the cancer ever outlasts the standard treatment. And it cleared its thirty-fifth country before lunch.

More indications. More data. More countries. Every few weeks the net under these patients gets wider, not narrower. No quarterly number can take that back.

So if you are holding this and your stomach dropped today, start with that fact. Then let me walk you through the rest, in plain terms, and sort the real worry from the scary-looking one.

Three things landed this morning. A pivotal first-line trial hit its goal. The quarterly financials came out. And the drug was approved in Israel. One genuine turning point, one scary-looking report, one small win. Take the scary one first, because it is the one most likely to be misread.

Was it a good quarter for the business? No. Revenue went backward for the first time in two years, and the headline loss is enormous. Let us say that plainly, and then let us be precise about which part is a real problem and which part only looks like one.

THE NUMBERS THAT LOOK LIKE A DISASTER, AND MOSTLY ARE NOT

The headline is a loss of about 185 million dollars for the quarter, and roughly a billion for the year so far. Read fast, that sounds like a company bleeding out.

It is not, and here is the grounded reason.

The company spent about 75 million dollars of actual cash this quarter. Not 185. Not a billion. About 75.

The rest is non-cash. The company carries a loan from its founder and some warrants that, under the accounting rules, get re-valued every quarter against the share price. When the share price rises, those are marked higher, and it shows up as a "loss," even though not a dollar left the building. The stock moving up is what inflates the number. It is paper, and it reverses. This quarter's paper loss was actually smaller than last quarter's.

So judge it by cash. On cash:

- The company ended the quarter with about 334 million dollars on hand

- That is down only about 23 million from the quarter before

- The drug is cheap to make: the cost of making it is only a sliver of what it sells for, roughly 97 cents of every revenue dollar is gross profit. That number is flattered a little by early-launch accounting and will ease back as normal manufacturing costs flow in, but the underlying economics are genuinely strong

One thing not to gloss over: cash barely moved not because the business pays for itself yet, it does not, but because the company raised about 53 million during the quarter to cover the burn, mostly by selling stock into the market and from warrants being exercised. They can raise money when they need it, and the founder's loan still sits behind them as a backstop. That is a real strength. It is not the same as self-funding, and this post will not pretend it is.

THE ONE THING ACTUALLY WORTH WATCHING

Here is the genuine, if small, yellow flag, the part the cheerleaders skip.

Revenue slipped from about 50.7 million last quarter to 48.7 million this quarter. Under 4 percent. It is the first time the quarterly number has gone backward after two years of climbing.

Why? Nobody outside the company knows, and the company did not say. The most likely read is that new patient starts softened for a quarter, in a drug still selling into one fairly small group of patients, possibly squeezed by the long-running shortage of the BCG it is paired with. A wobble on a small base, not a collapse.

And notice what the wider loss was really about. The company spent more this quarter, research and development jumped over 10 million, because it is pushing its whole pipeline forward. That is money going into the future, on purpose. The soft spot is the revenue line, not the spending.

So watch the revenue trend. Not the scary headline loss, which is paper.

THE DOOR THAT ACTUALLY MATTERS

Now the piece worth understanding, because it is the biggest thing that happened today and it is easy to miss under the numbers.

A little plain English first. For about fifty years the standard first treatment for this cancer has been BCG, a weakened bacterium placed in the bladder to wake the immune system against the tumor. When BCG stops working, the patient is called unresponsive, and the options narrow toward surgery to remove the bladder. Everything this drug was approved for until now has been that salvage setting, patients BCG already failed, a couple of thousand people a year per group.

Today's trial is different. It tested the drug first-line, added to BCG from the very start, to keep the cancer from ever becoming unresponsive at all. And it worked, beating BCG alone. First-line is the whole high-grade group, before anyone fails, several times the size of that salvage pool, on the order of ten thousand or more Americans a year, the largest BCG-treated group in this disease. Today was the key turning in the lock of that far bigger door.

One clarification, because it is already being muddled online. The trial has two patient groups, Cohort A and Cohort B. Only Cohort A read out, it is positive, and it is the one the company files on. Cohort A alone supports the first-line approval they are chasing now. The second group is a separate cohort, a different set of patients measured a different way, reading out on its own schedule. It is not a gate on the Cohort A filing. The important data already landed.

WHEN THIS TURNS INTO MONEY

Not next quarter, and no one should promise you otherwise.

But here is the quiet part worth sitting with. The group of patients this drug can be sold to grew substantially last month, when the second-tumor approval landed. Europe just opened its first sales. And the biggest group of all, the first-line patients, is now heading into filing. The fuel for a much larger sales line is in the tank. When it combusts is the part no one can promise.

The reason none of it reached today's number is timing. The second-tumor approval and the first Europe sales both landed after this quarter closed, so they are a Q4-and-beyond story. The first-line filing is targeted for year-end 2026; any approval, and the first revenue from it, would be a 2027 story at the earliest, not this year. The country-by-country approvals, Israel, the Gulf, Europe, are each small alone and add up slowly.

So 2027 is the year the catalysts start turning into revenue: a maturing second-tumor ramp, Europe building, a first-line decision, more countries stacking. That is the shape of it. It is a build, and the tank is now full.

WHAT TO EXPECT FROM HERE

If you came here expecting one trial win to send this straight up overnight, history says that is not how a company like this tends to move. A business still selling into one small group of patients, that just posted a soft revenue quarter, does not turn the whole story around on a single good headline. It gets there over several quarters, as the catalysts actually land, the approvals, the expansions, the countries, the return to growth. The path is lumpy, and no one can time it.

That is not a reason to despair. It is a reason to be clear-eyed about the clock. The science took a real step today. The financial scare is mostly an accounting mirage. The one real soft spot is a revenue quarter to watch. And the things that make 2027 matter are finally in motion.

WHAT IT MEANS, IN PEOPLE

Come back to where we started, because it was always the point.

First-line means reaching people earlier. Before the years of waiting to see if BCG holds. Before the organ is ever on the table. If today's result holds through filing and approval, more people never travel the narrowed road at all.

When the database for this trial locked last month, the founder, @DrPatrick, wrote one line:

"The archaic era of painful chemotherapy will come to an end in our lifetime. Chemo free, and save our lymphocytes, is the 21st century mantra."

Today the trial behind that sentence met its mark. Not the whole promise. One real step toward it, in the biggest door this disease has.

The medicine is ANKTIVA. The trial was its first-line test, ANKTIVA plus BCG from the start. The date was November 9, 2026. Three announcements, one of them a genuine turning point, and the only thing still behind the curtain is how wide the door swings.

No price target. No promise. The numbers that settle it are still coming.

But somewhere is a person who has not heard the word cancer yet, who will one day keep their bladder and never know this morning happened. That is who today was for.

$IBRX - What's going on with the stock price? Wrong question.

The right questions: What if medicine could be revolutionary? What if we could save lives without doing harm?

Do. Not. Harm.

$IBRX The FDA said yes three months early. The share price fell about 20%. The forums flooded with fear. Read that back. The news got better. The mood got worse. Here is what the fear is missing.

WHAT ACTUALLY HAPPENED

Ten days ago, on October 14, the FDA approved ANKTIVA for a new group of bladder-cancer patients, roughly three months ahead of its own deadline. It was the first medicine ever cleared for them, in a disease where the only prior option had been surgery to remove the bladder.

Investors had waited a long time for that yes, and many had bought in ahead of it, expecting the day to feel like a win.

It didn't. The price fell, and the forums turned dark.

The reason has nothing to do with the medicine. When an event everyone has been anticipating finally arrives, the excitement that ran ahead of it drains away. Traders even have a name for it: selling the news. It is a fact about the crowd, not the cure.

FOUR FEARS, AND NONE IS ABOUT THE MEDICINE

Scroll the boards and the worry is almost never that the science failed. It is about money, and it takes four shapes.

- Priced for perfection. The good news is already in the stock, so now the sales have to prove it. Show me, they say. Do not tell me

- The competition is coming. Johnson and Johnson has a bladder treatment that does not need BCG and is already selling. The fear is that it takes the market

- Another raise. The company has leaned on selling shares before, and each one can leave today's owners with a smaller piece

- The chart says down. Some chart-readers say the peak has passed and the big money is quietly selling, so the feeds brace for a months-long slide. The chart does not lie, they repeat

Four fair worries. And not one of them is that the medicine stopped working. Start with the loudest: show me the money.

WHAT NO ONE CAN HONESTLY TELL YOU

Here is the hard part, and it cuts against both sides. Nobody outside the company can give you that number yet.

The quarter that just ended is over, so its sales already happened. The exact number is sealed inside the company until it reports, which could be any day now. The quarter running now, no one knows at all.

Nobody knows the next trial's result before the results are opened. Nobody knows the final price in a new country. Only the management team sees the orders as they land.

Every confident prediction you are reading right now, bull or bear, is a guess. Mine included.

A chart is a guess too. It can draw where the price has been, but it cannot see a trial result that has not been revealed or a quarter that has not been reported. The lines only know the past.

And the scariest claim in that bundle, that the big money is quietly selling, is not data on what any investor actually did. It is a number the charting app builds out of the same price and volume already on the chart. The chart talking about itself.

But prediction is not the only thing on the table. A great deal is already done: banked, and beyond the reach of any single quarter. So start there.

WHAT IS ALREADY BANKED

Not forecasts. Things that have already happened:

- A second form of the disease, cleared ten days ago. This bladder cancer comes in more than one form, and the October approval was the first the FDA has ever granted for this one. On our read of the patient numbers, that roughly doubles the US pool ANKTIVA is cleared to treat

- The first form, cleared back in 2024, now with a multi-year track record. In those earlier patients, the longest responses have run past 53 months, and 84% of those who responded still had their bladder at three years

- Europe, open. 30 countries cleared it in a single approval, with a commercial partner and over 100 sales, medical and marketing staff in place. The first vials have already come off the line, packed and labeled in German, and the company's founder posted the photo of that finished run himself

- The Gulf, open. The UAE granted the widest label this drug holds anywhere on earth, covering both bladder cancer and an advanced lung cancer the US has not approved it for at all

A weak quarter does not undo any of it.

HOW ANKTIVA IS ACTUALLY GIVEN

Here is the part that changes the whole picture, and almost nobody spells it out.

ANKTIVA is placed directly into the bladder together with BCG, in a urologist's office. It does not happen once.

It opens with an induction course: one treatment a week for six weeks. Six doses. At the three-month check, if the cancer is not fully cleared, that six-week course can be run a second time.

Then maintenance begins, and it is long. A round of three weekly treatments repeats at months 4, 7, 10, 13, and 19. For patients still responding, it continues with another three-treatment round at months 25, 31, and 37.

Add it up. One responding patient can receive on the order of 30 separate in-office treatments, stretched across about three years.

So one patient is not one sale.

Each treatment is billed on its own, as it is given, at roughly 35,000 dollars a dose. None of it is paid up front. The first year alone runs to around half a million dollars, and that is only the first year.

The rounds in years two and three are billed when they happen, still to come. A full course climbs toward a million dollars, arriving in pieces across the three years, never in one lump.

These are list prices, and the company collects less after rebates and patient assistance. But the shape is the point: the money recurs, per patient, year after year.

IS THE GROWTH EVEN REAL?

This is the fear under the fear: that the sales are a sugar high. A rush of early adopters, then a fade.

But look at what we just counted. Because every responder is on a multi-year course, the base does not reset each quarter. It stacks, as new patients start on top of the ones still cycling through their maintenance rounds.

The record so far: eight quarters in a row of growth, more than 50 million dollars in the most recent one, nearly double a year before. It kept growing straight through Johnson and Johnson's launch.

The honest mechanism: to keep climbing, it needs a steady flow of new patients in the top. That is exactly what each new approval delivers, by reaching earlier into the disease.

It started with the hardest cases, carcinoma in situ (the flat, high-grade form), in patients whose cancer had stopped responding to BCG. Ten days ago it added the papillary form (tumors that grow on stalks), in that same BCG-unresponsive group. And the trial reading out soon goes earlier than either: BCG-naive patients, given ANKTIVA with BCG from the very first treatment. That is the largest pool of all.

Each step widens the mouth of the funnel.

And this is an IL-15 immune therapy, not a one-cancer drug. Bladder is where it earns today. It is in trials well beyond it. Bladder is the floor, not the ceiling.

THE APPROVALS THAT AREN'T IN THE NUMBERS YET

A fair question: more than thirty countries approved, so where is the overseas money?

Straight from the filings: through last quarter, every dollar of product sales still came from the United States. International has barely begun.

Now turn that over.

The US alone is carrying the whole thing, and still growing, before Europe or the Gulf add a single dollar. Every one of those approvals is upside that has not reached the books yet.

Timing, honestly: Europe's first supply was only produced in August, so overseas revenue starts to appear over the next quarter or two and into next year. No one can name the exact quarter it turns meaningful. That number starts near zero. From here it has only one way to go: up.

WHAT TO WATCH NEXT

Dates, not promises:

- The trial in patients earlier in the disease has finished collecting its data, and the company expects the results in November

- A filing to expand the approval to more patients is on track for the end of this quarter

- The next revenue update could land any day now.

Watch them. Wait for the real numbers.

THE CATCH

The honest other side, because a piece that only reassures is worth nothing:

- This company still spends more than it earns, and it has said it may need to raise money. Owners today could hold a smaller slice later

- One quarter can look weak for reasons that have nothing to do with the medicine

- The competition is real, and it is not standing still

- None of the facts above promise anything about what the price does next. None of this is advice

ASK WHAT THEY GAIN

Think back to everything the feeds have been screaming. It is overvalued. The competition will take the market. Another raise will shrink your slice. The chart says it only falls from here.

Loud, confident, and everywhere at once.

So here is the last tool, and the most useful one of all. Before you believe any of it, including this post, ask one question: what does this person gain if I believe them?

The fear you read comes from very different places.

- Some of it is real. A holder who is genuinely scared, thinking out loud. The fear is honest, even when the conclusion is wrong

- Some of it is a swing trade. Someone who sold higher and would love to buy back cheaper, so they talk it down. Someone who is short and makes money the moment you panic and sell

- Some of it is a rival's corner. People who own a competing stock and want this one to look weak

- And on any name with this much attention, some posts are simply paid to move you, in both directions at once. You usually cannot tell which, so do not burn energy hunting villains

You do not need to know who is who. You only need the question: what does this person gain if I believe them? Ask it, and most of the fear quietly loses its grip.

Ask it of me too. My intent is in the open: to pull the facts out from under the mood and hand you every one to check. Judge whether I did.

Here is what the fear is missing.

Ten days ago, patients with this cancer had no medicine, only surgery. Today they have a medicine, cleared early, in more than thirty countries, keeping bladders in bodies.

That happened. It is still true this morning, whatever the screen says.

Red numbers, then green, then red again. None of it reaches the patient who still has their bladder, and their life, because ANKTIVA exists.

That is the thing. Not the number. The life.

P.S. Face your fear and fear disappears.

$IBRX Picture a man named Frank being told the cancer in his bladder has come back.

Most likely a man, because bladder cancer strikes men about four times as often as women.

Frank already did the standard treatment. It held for a while. Now it is back, and it is the high-grade, aggressive kind.

There are drugs for this moment. The cruel part of Frank's case is that none of them were approved for his exact kind of tumor. So the one real thing his doctor could offer him was surgery: take the bladder out. The whole organ. Surgeons call it a radical cystectomy. For Frank it means living the rest of his life with a bag on the outside, or a new bladder built from a piece of his own intestine.

Yesterday, October 14, 2026, that stopped being the only road.

If you have been following along, you know the project we are nearly through: a four-part series putting real numbers on what this company could become ten and twenty years out, one cancer and one country at a time.

Today we step off that for a minute.

Because yesterday was not a projection. It was one real step on that long road, actually taken. And a step that lands on men like Frank is worth stopping to look at on its own.

WHAT ACTUALLY CHANGED YESTERDAY

The US Food and Drug Administration widened the approval of a medicine called ANKTIVA, given together with BCG, to cover this exact group for the first time.

A few plain terms first, because they run through everything below.

The kind Frank has, and the kind yesterday's approval is about, is called non-muscle-invasive bladder cancer, or NMIBC for short. The tumor sits in the lining of the bladder and has not grown into the muscle wall yet. Caught at this stage, the bladder can often be saved.

BCG is the old standard. A weakened bacterium placed into the bladder that wakes the immune system up against the tumor. It has been the front-line treatment for about fifty years. When the cancer comes back anyway, the patient is called BCG-unresponsive.

Bladder tumors come in two shapes. The flat kind is called CIS, short for carcinoma in situ. The raised kind is called papillary. Those two names, CIS and papillary, are the whole story from here.

Until yesterday, ANKTIVA was approved for patients whose cancer included CIS. People with only papillary tumors, and no CIS, were left out.

That is Frank. His tumors are papillary, with no CIS, and for that exact group there was no approved drug at all. It is the reason the only thing his doctor could offer was surgery.

Now that group is in. It is the first treatment ever approved for them.

THIS IS NOT JUST A BLADDER DRUG

It is easy to file this under bladder cancer and move on. That undersells it badly.

ANKTIVA is an IL-15 superagonist. In plain terms, it rebuilds the body's own front-line cancer killers, the natural killer cells and the memory T cells. Bladder is simply where it crossed the finish line first.

The same engine is why the company is not running one trial, it is running a whole plan. Back in February, in a detailed press release, ImmunityBio put it on the record: a three-year program it calls Cancer BioShield, more than thirty trials across about ten tumor types. The same medicine, aimed at cancer after cancer, lung and pancreatic and liver among them, and at the immune collapse itself, the lymphopenia that cancer treatment causes, and at sepsis. It is already approved for lung cancer in the Gulf.

That plan is exactly what our four-part series has been sizing. This post steps off it to look at the one door that just opened. But the key that opened it is the same key built for all the others.

THE NUMBER THAT MATTERS IF IT IS YOUR BLADDER

In the trial behind this approval, about 82 percent of these patients still had their bladder three years later.

Three years on, more than four out of five had not needed the operation that removes the organ.

That is what "keep your bladder" looks like as a number, not a slogan.

THE MISTAKE THE EXCITEMENT IS ABOUT TO MAKE

Here is where the story is about to get misread. Let me correct it, because the real number does not need the exaggeration.

You will hear that papillary disease is the large majority of this cancer, so the opportunity just multiplied several times over. That is wrong.

The old approval already covered anyone whose cancer included CIS, even if they had papillary tumors next to it. So most people with both were already eligible.

The genuinely new group is the patients with papillary tumors and no CIS at all.

On grounded US numbers, the group already covered runs on the order of 2,000 new patients a year, and the newly added papillary-only group is about the same size. So adding it roughly doubles the population this medicine is approved to treat in bladder cancer.

About two times, not five. A doubling is already a large event. It does not need to be inflated to be worth your attention.

SO WE SAT DOWN AND DID THE MATH

Since the approval, the numbers have been flying. Some say it triples the market. Others say five times. Most just say huge. So here is the actual chain, built from the primary sources, one step at a time.

Start with every new US bladder cancer, about 84,500 a year.

- Roughly three in four are non-muscle-invasive, still in the lining: about 63,000

- Only the high-grade ones, and only after BCG stops working, are in play. That narrows hard, to low thousands a year

- That BCG-resistant group is what splits in two: the CIS kind, approved in 2024, and the papillary-only kind, approved yesterday

The single number that decides doubles-or-triples is that split. So we read it straight off five published trials of this exact group, and in every one the CIS share lands nearer half than a third:

- Keytruda's trial: 43 percent CIS
- ANKTIVA's own: 53 percent
- The SWOG study: 57 percent
- Cretostimogene: 67 percent
- Adstiladrin: 68 percent

Five independent reads, all clustering around half. So the papillary-only group is a comparable slice, not a bigger one. A doubling, not a multiple.

The reason it lands there is worth a sentence: papillary is the more common shape when the cancer is first found, but CIS shrugs off BCG more often, so by the treatment-resistant stage this drug is for, the two are about even.

Now the honesty, because it is the whole point of doing the math in the open. Those five trials are a strong proxy, not a population census, so treat the doubling as our best-supported read, not a settled fact. The exact split is the one input still worth arguing about. And note which way we rounded: we used the low end of every range, so the company's own filings put all of these counts two to three times higher. If the number is wrong, it is wrong on the low side.

WHAT THE NEW GROUP IS ACTUALLY WORTH

First, do not do the lazy thing. ANKTIVA lists at about 300,000 dollars for a course, so the temptation is to multiply: 2,000 patients times 300,000 is about 600 million dollars a year. Throw that out. Nobody pays the full sticker, and no drug reaches every patient, so that number is always make-believe.

The clean way needs almost no assumption, because the company already sells this exact drug for this exact disease. The first group alone, the one the old label covered, already brings in about 200 million dollars a year. And it got there fast: from approval in April 2024 to that run-rate in about two years.

The new group is about the same size, and it does not start from scratch. Same sales team, same reimbursement, same doctors who already know the drug. So there is no reason it earns much less than the first group.

Put simply: a second group about the size of the first roughly doubles the bladder business over time, toward 400 million dollars a year. A direction, not a forecast.

And here is the part worth sitting up for. That 200 million is not a finish line. It is a snapshot of something still moving: the first group alone grew from about 113 million dollars last year to a 200-million run-rate now, and it has not stopped.

So the new group does not add a second 200 million on top of a number standing still. It adds a second engine to one that is still climbing.

Here is the easy way to picture it. If both groups had been approved on the same day, the company would not be sitting at 200 million in bladder today. It would be near 400, and still rising. The approval just split that into two steps, two years apart.

SO WHEN DOES THE MONEY ACTUALLY SHOW UP?

This is the question every holder is really asking. It is approved now, in a market the company already serves, for a group the same size as the one it already sells to. So does next quarter just double?

No, and it is worth being honest about why.

- Doctors have to learn the label changed and start using it for the new group. That takes a few quarters, not a few days

- The money per patient builds over the treatment, the induction first, then maintenance across months, so even once someone starts, the revenue comes in pieces, not one lump

- Coverage and billing for the new group have to settle in with the payers

So do not expect the fourth-quarter print, or the first one of 2027, to suddenly be twice the size.

But do not expect a crawl either, and here is the key point. The first group needed about two years partly because it was building everything at once, the sales force, the reimbursement, the physician awareness, all while finding its first patients. The new group inherits every bit of that, finished. It only has to reach patients who are already in the system, some of them waiting.

So it should ramp faster than the first group did, not slower, closer to a year to its own run-rate than two, though nothing here is instant.

And there is no separate line to watch for it. The company reports one bladder number, not a split by group. So the honest tell is just the trend: bladder revenue climbing quarter after quarter as the new patients come on. Give it several prints, not one. A single quarter proves nothing; a steady climb across a few is the new door filling in.

THE REST OF THE WORLD TENDS TO FOLLOW

Here is the optimistic case, and it is not a stretch. ANKTIVA is already cleared in more than thirty countries, each of them following the lead of the original US approval. And the UAE has already matched this exact papillary step, the first country to do it. So the expansion spreading is not a wild hope. It is the base case, along a path these regulators have walked before. Not signed everywhere yet, but the precedent is doing the heavy lifting.

Now the size of it, with one honest guardrail: you cannot just multiply the US by the world and keep US prices, because approval, price, and access all differ country by country. But the patient count scales cleanly, because the disease does not care about borders.

Break it down:

- The world sees about 614,000 new bladder cancers a year, against roughly 84,500 in the US. That is about seven times as many

- Scale the papillary-only group the same way: 2,000 US patients times seven is about 14,000 across the entire world. Independent review agreed with the arithmetic

- Take the US back out, and the rest of the world, every country except America, is about 12,000 a year. Six times the US, which is exactly right: seven times for the whole world, minus the one times that is the US itself.

So think of it in engines, where one engine is a group this size running at US scale, about 200 million dollars a year. The US has two of them now, CIS and papillary, heading toward 400 million together. The rest of the world's papillary group, around 12,000 patients, is six times the 2,000 the US just approved, so six engines' worth of patients. At the lower prices paid outside America, that works out to four to five more engines of revenue.

Picture them all running at once, the way we pictured the two US engines. Two engines in the US, plus four to five across the world, would put the whole thing north of a billion dollars a year, somewhere in the 1.2 to 1.4 billion range, if they were all running together right now, as we speak. And like the US number, that is not a ceiling but a floor still climbing.

They will not all switch on at once. Prices and reach outside America run lower, and each country is its own approval. So bank less than that, and treat it as the size of the room, not a forecast. But that is the room, and the door to it has already been opened once, in the UAE.

THE BIGGER DOOR STANDING RIGHT BEHIND THIS ONE

Here is the part the headline misses. The door that opened yesterday is not the only one, and it is not even the biggest.

Everything so far is the salvage setting: patients whose cancer already came back after BCG. The first door, approved in 2024, was the CIS version of that group. Yesterday's door is the papillary-only version. Together they are the people medicine had already failed once.

There is a larger door behind them: treating this cancer first-line, with ANKTIVA added to BCG from the start, before the cancer ever becomes unresponsive. That is the whole high-grade group, before anyone fails BCG, so it is far bigger. Take the same 63,000 new cases a year and keep the high-grade ones who get BCG, roughly one in five on the conservative end, and you are at about 12,000. That is several times the size of the door that just opened, and the company's own filings put it higher still.

And that door is the company's next planned filing, expected around the end of this year.

Then scale it the way we just scaled the current one. The first-line door is already six engines in the US. Across the world, in patient terms, it balloons to dozens, the single biggest pool in this whole disease. What that turns into in dollars depends on approvals and prices that do not exist yet, so hold it as the ceiling, not a number to bank. But that is the ceiling.

So yesterday was real, and it matters. It was also a smaller, nearer step before a bigger one.

SO WHAT EXACTLY WILL HE SAY ON FRIDAY?

Here is where it gets interesting, and honest: we do not know. But over the past week, the founder, Patrick Soon-Shiong, has flagged this same fireside chat in two separate posts, about two different things.

1. Bladder. The day the approval landed, he posted that he is looking forward to discussing the status of treating non-muscle invasive bladder cancer this Friday, October 16. Read that carefully: he did not say he would discuss the approval. He said the status of treating the whole disease. So is Friday a victory lap on the door that just opened, or does he also open the next one and show fresh data from the first-line program heading toward filing?

2. Every other cancer. A week ago, when we posted the piece sizing the whole three-year plan, he quote-tweeted it and said he would give a status update on those trials at this same fireside chat. Not just bladder. The lung, the pancreatic, the liver, the rest of the Cancer BioShield board.

And the timing is not random, because two clocks are near zero right now. The third quarter closed on September 30, and in a couple of recent quarters he has pre-announced preliminary sales within two weeks of the close, which would be right about now. And the first-line trial finished enrolling its main group back in February, with a filing guided for the end of this year, so the data behind it is due to mature right about now.

So put it together. Friday is not just a bladder update. It is a status report on the whole plan, from the one door that just opened to the rest of the board behind it. Either clock could strike, or neither, and it is just a victory lap. We are not going to pretend to know which. But he did not pick a random week for this, and he did not pick the narrow words for it. That is worth watching, whichever way it breaks.

NOW COUNT IT IN PEOPLE, NOT DOLLARS

Step back from the money, because it was never really about the money.

Those roughly two thousand Americans a year are not a market. Each one is a person who was about to lose an organ and now has a real shot at keeping it instead.

So picture one. A father at the dinner table for his kid's birthday this year, not in a recovery ward. Someone who keeps their body whole, skips the bag, and keeps the cancer from spreading past the bladder. Two thousand of them, every year, in this country alone.

AND THAT IS JUST ONE COUNTRY

If this approval travels the way the earlier ones have, the same group outside the US is on the order of twelve thousand people a year.

Twelve thousand more families, every year, where someone keeps their bladder instead of losing it. It is not approved out there yet, so hold it as a maybe. But that is the real shape of the prize: a surgery avoided and a life left whole, one person at a time, until it is a stadium full of them a year.

IT IS NOT ONLY THE PATIENTS

Here is the part that rarely gets said out loud. This is not only about the people who take the drug.

It is also about the people who funded it. The shareholders who put their own money behind this company and held through the dark stretches, the quarters of going-concern warnings and a beaten-down price that punished belief. They are a reason the lights stayed on long enough for a day like this to arrive.

If the science keeps delivering, they get something too: a real chance to change their own families' futures. No price target, no promise it pays off, and plenty of ways it can still go wrong. But this is the kind of day they have been holding for.

None of this is advice, and I am not promising anyone a return. The patient counts are sourced estimates on the conservative end. The price is a number I chose and labeled. The share is a dial, and it is in your hand.

WIN, WIN, WIN

Yesterday the list of people who get to keep their bladder got longer. The medicine is ANKTIVA. The date was October 14, 2026. And men like Frank, out of options the day before, woke up with one.

So count the winners:

- The founder @DrPatrick and his team, chasing a goal most people called impossible, building the legacy he means to leave

- The patients, like Frank, who keep their bodies and their time: who make it to the grandkid's ball game, who walk their daughter down the aisle, who get the anniversaries and the ordinary Tuesdays that the surgery would have taken

- The believers who funded the whole thing, who held through the dark years when plenty called them fools, who finally see a piece of why they held, and, if the science keeps delivering, the chance to do for their own families what Frank now gets to do for his.

A true win, win, win.